AstraZeneca says FDA advisory committee won't support CKD treatment for approval, partner FibroGen stock plungesMarket Watch • 07/16/21
FibroGen Staring At Multi-Year Lows Following Adverse Roxadustat AdCom Verdict; How Hard Will The Stock Likely Fall?Benzinga • 07/16/21
FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney DiseaseGlobeNewsWire • 07/15/21
Ahead Of AdComm AstraZeneca, FibroGen's Roxadustat Hit With Safety, Efficacy QuestionsBenzinga • 07/13/21
Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney DiseaseGlobeNewsWire • 06/25/21
FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune DiseaseGlobeNewsWire • 06/17/21
Pamrevlumab Included in Pancreatic Cancer Action Network's Adaptive Clinical Trial PlatformGlobeNewsWire • 06/16/21
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline - FGENNewsfile Corp • 06/12/21
DEADLINE TODAY: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the FirmNewsfile Corp • 06/11/21
Final Day to Actively Participate: FibroGen, Inc. (FGEN) Class Action - Bronstein, Gewirtz & Grossman, LLCNewsfile Corp • 06/11/21
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited ShareholdersNewsfile Corp • 06/10/21
FINAL DEADLINE TOMORROW: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the FirmPRNewsWire • 06/10/21
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGENNewsfile Corp • 06/10/21
DEADLINE TOMORROW: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the FirmNewsfile Corp • 06/10/21
Kessler Topaz Meltzer & Checker, LLP: Final Deadline Reminder for FibroGen, Inc. Investors - FGENNewsfile Corp • 06/10/21
FGEN LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of FibroGen, Inc. ShareholdersNewsfile Corp • 06/09/21
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - (FGEN)Newsfile Corp • 06/09/21